This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rider, L. G. Articles by Miller, F. W. Search for Related Content PubMed PubMed Citation Articles by Rider, L. G. Articles by Miller, F. W.

Next Article 

Clinical and Diagnostic Laboratory Immunology, Jan 1995, 1-9, Vol 2, No. 1
Copyright © 1995 by the American Society for Microbiology. All rights reserved.

Laboratory evaluation of the inflammatory myopathies

LG Rider and FW Miller
Molecular Immunology Laboratory, U.S. Food and Drug Administration, Bethesda, Maryland 20892.

The laboratory plays an important role in the diagnosis, evaluation, and classification of the heterogeneous group of diseases known as the IIM, which are characterized by chronic muscle inflammation. Serial measurements of the levels of muscle-derived enzymes in serum are the traditional laboratory studies used to follow the clinical course of patients with IIM, although other laboratory tests can also be useful in assessing myositis disease activity. Several markers of immune system activation, including cytokines and lymphocyte markers, show promise as possibly more sensitive measures of myositis disease activity. Discovery of a unique group of MSAs over the past decade has provided an immunologic basis for defining relatively homogeneous subsets of patients who share similar clinical features, disease courses, and responses to therapy. Future investigations of novel immunologic activation markers, as well as the cloning and expression of target autoantigens of the MSAs, should allow better diagnostic assays, enhanced prognosis, and a better understanding of the pathogenesis of these disorders.

This article has been cited by other articles:

• Ryan, A., Nor, A. M., Costigan, D., Foley-Nolan, D., El-Rafie, A., Farrell, M. A., Hardiman, O. (2003). Polymyositis Masquerading as Motor Neuron Disease. Arch Neurol 60: 1001-1003 [Abstract] [Full Text]  
• Sultan, S. M., Ioannou, Y., Moss, K., Isenberg, D. A. (2002). Outcome in patients with idiopathic inflammatory myositis: morbidity and mortality. Rheumatology (Oxford) 41: 22-26 [Abstract] [Full Text]  
• Miller, F. W., Rider, L. G., Chung, Y.-L., Cooper, R., Danko, K., Farewell, V., Lundberg, I., Morrison, C., Oakley, L., Oakley, I., Pilkington, C., Vencovsky, J., Vincent, K., Scott, D. L., Isenberg, D. A. (2001). Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. Rheumatology (Oxford) 40: 1262-1273 [Abstract] [Full Text]